 GSK PLC LSE:GSK, NYSE:GSK has reported that a US Food and Drugs Administration FDA committee voted that the benefits of its drug, daprodustat outweighed risks for adult dialysis patients with anaemia of chronic kidney disease CKD, but not for those not undergoing dialysis. The company said the FDAs Cardiovascular and Renal Drugs Advisory Committee CRDAC voted 13 to three in favour of saying the drug benefitted patients on dialysis, but five to 11 against for non-dialysis patients. 